Table VII.
Clinical and biochemical evaluations of stroke patients: parameters at the baseline (before) and after an application period (after) by means of SSS and FIM scale and biochemical indices (mean±SED) (162).
| Parameter | ME-3 group | Placebo group | ||
|---|---|---|---|---|
| Clinical parameter | Before | After | Before | After |
| SSS | 33 ± 13 | 42 ± 122 | 37 ± 12 | 45 ± 91 |
| FIM | 21 ± 19 | 40 ± 233 | 32 ± 16 | 50 ± 16,1,4 |
| Biochemical indices | ||||
| LDL-cholesterol (mmol/L) | 3.9 ± 2.2 | 3.8 ± 1.9 | 3.2 ± 0.8 | 3.2 ± 1.14 |
| oxLDL (U/L) | 121 ± 35 | 109 ± 351 | 130 ± 23 | 128 ± 224 |
| DC (μmol/L) | 50 ± 9 | 45 ± 83 | 45 ± 16 | 45 ± 14 |
| GSSG (μmol/L) | 64 ± 16 | 52 ± 182 | 73 ± 28 | 71 ± 184 |
| GSSG/GSH | 0.07 ± 0.01 | 0.05 ± 0.011 | 0.07 ± 0.02 | 0.06 ± 0.01 |
| TAA (%) | 34 ± 1 | 46 ± 32 | 37 ± 1 | 35 ± 414 |
DC, diene conjugates; FIM, Functional Independence Measure; GSSG, oxidized glutathione; GSSG/GSH, glutathione redox ratio; LDL, low-density lipoprotein; oxLDL, oxidized low-density lipoprotein; SSS, Scandinavian Stroke Scale; TAA, total antioxidant activity.
1
p < 0.05,
2
p < 0.01 and
3
p < 0.001 as compared to baseline value;
4
p < 0.05 as compared to the ‘After’ values in the ME-3 and placebo groups.